Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBT Margin (2016 - 2025)

Historic EBT Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to 26.86%.

  • Ascendis Pharma A's EBT Margin rose 1429100.0% to 26.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.3%, marking a year-over-year increase of 566900.0%. This contributed to the annual value of 91.98% for FY2024, which is 646500.0% up from last year.
  • Latest data reveals that Ascendis Pharma A reported EBT Margin of 26.86% as of Q3 2025, which was up 1429100.0% from 22.15% recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's EBT Margin ranged from a high of 12.06% in Q4 2024 and a low of 13154.79% during Q2 2021
  • For the 5-year period, Ascendis Pharma A's EBT Margin averaged around 1883.73%, with its median value being 303.21% (2024).
  • In the last 5 years, Ascendis Pharma A's EBT Margin crashed by -65365500bps in 2021 and then surged by 118339200bps in 2022.
  • Over the past 5 years, Ascendis Pharma A's EBT Margin (Quarter) stood at 123.27% in 2021, then plummeted by -616bps to 882.6% in 2022, then skyrocketed by 97bps to 26.79% in 2023, then skyrocketed by 55bps to 12.06% in 2024, then plummeted by -123bps to 26.86% in 2025.
  • Its EBT Margin stands at 26.86% for Q3 2025, versus 22.15% for Q2 2025 and 92.68% for Q1 2025.